Evaluating fertility and ovarian function in female childhood cancer survivors
PReserving Fertility and Quality of Life IN Belgian Female Paediatric CancEr SurvivorS
This study is testing how certain cancer treatments affect the fertility and ovarian health of women who survived childhood cancer to see if they can find new ways to predict ovarian problems later on.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 340 (estimated) |
| Ages | 18 Years to 50 Years |
| Sex | Female |
| Sponsor | Centre Hospitalier Universitaire de Liege Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 3 sites (Liège, Wallonia and 2 other locations) |
| Trial ID | NCT06626282 on ClinicalTrials.gov |
What this trial studies
This project aims to assess the impact of low-intermediate dose alkylating agents and ovarian cryopreservation on ovarian function in female survivors of pediatric cancer. It will involve a cohort of female survivors aged 18 and older, analyzing their ovarian health and fertility outcomes. The study will also seek to identify new epigenetic markers that could predict the risk of premature ovarian insufficiency. Data will be collected from the Paediatrics Late Effects database and through fertility evaluations at specialized centers.
Who should consider this trial
Good fit: Ideal candidates are female survivors of pediatric cancer who were diagnosed before the age of 17 and are now at least 18 years old.
Not a fit: Patients who have not survived childhood cancer or those diagnosed with cancer after the specified age will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance fertility preservation strategies and improve the quality of life for female childhood cancer survivors.
How similar studies have performed: Other studies have shown promise in fertility preservation techniques for cancer survivors, making this approach both relevant and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Child and adolescent female patients included in the Paediatrics Late Effects Project: * diagnosed with cancer1 between 01/01/2004 and 31/12/2018 * \<17 years old at diagnosis * treated at CHU Liège site Citadelle or CHC, Cliniques Universitaires Saint-Luc and HUDERF * alive * ≥ 18 years-old at time of recruitment. Exclusion Criteria: * Cancer diagnosis for controls
Where this trial is running
Liège, Wallonia and 2 other locations
- Hopital de la Citadelle — Liège, Wallonia, Belgium (Recruiting)
- Cliniques Universitaires Saint-Luc — Brussels, Belgium (Not_yet_recruiting)
- Huderf — Brussels, Belgium (Not_yet_recruiting)
Study contacts
- Study coordinator: Bianca David, MD
- Email: bianca.andreea.david@citadelle.be
- Phone: 32 4 321 87 39
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.